TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05405595: ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Sponsor: Adagene Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 186 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,788,170

Rescue Site Savings

+$1,845,690

Unlock Full NCT05405595 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05405595 Rescue Dossier →